Intervention Review

You have free access to this content

Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease

  1. Teguh H Sasongko1,*,
  2. Srikanth Nagalla2,
  3. Samir K Ballas3

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 28 MAR 2013

Assessed as up-to-date: 27 FEB 2013

DOI: 10.1002/14651858.CD009191.pub2


How to Cite

Sasongko TH, Nagalla S, Ballas SK. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD009191. DOI: 10.1002/14651858.CD009191.pub2.

Author Information

  1. 1

    Universiti Sains Malaysia, Human Genome Center, School of Medical Sciences, Kota Bharu, Kelantan, Malaysia

  2. 2

    Thomas Jefferson University, Department of Medicine, Division of Hematology, Philadelphia, Pennsylvania, USA

  3. 3

    Jefferson Medical College, Thomas Jefferson University, Cardeza Foundation for Hematologic Research, Department of Medicine, Philadelphia, USA

*Teguh H Sasongko, Human Genome Center, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kota Bharu, Kelantan, Malaysia. teguhharyosasongko@yahoo.com. teguhhs@usm.my.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 28 MAR 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Foucan 1998 {published data only}
  • Foucan L, Bourhis V, Bangou J, Merault L, Etienne-Julan M, Salmi RL. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. American Journal of Medicine 1998;104(4):339-42.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Aoki 1995 {published data only}
Falk 1992 {published data only}
  • Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. New England Journal of Medicine 1992;326(14):910-5.
Fitzhugh 2005 {published data only}
McKie 2007 {published data only}
  • McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. Journal of Pediatric Hematology/Oncology 2007;29(3):140-4.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Al Hosani 2005
  • Al Hosani H, Salah M, Osman HM, Faraq HM, Anvery SM. Incidence of haemoglobinopathies detected through neonatal screening in the United Arab Emirates. La Revue de Santé de la Méditerranée Orientale 2005;11(3):300-7.
American Kidney Fund 2008
  • American Kidney Fund. High Blood Pressure (Hypertension). www.kidneyfund.org/kidney-health/are-you-at-risk/high-blood-pressure.html (accessed 24 October 2010).
Anderson 1986
  • Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. Journal of Clinical Investigation 1986;77(6):1993-2000.
Ataga 2000
Ataga 2010
Becton 2010
  • Becton LJ, Kalpathi RV, Rackoff E, Disco D, Orak JK, Jackson SM, et al. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatric Nephrology 2010;25(8):1505-11.
Brousseau 2009
  • Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. American Journal of Hematology 2009;85(1):77-8.
Chandar 2007
  • Chandar J, Abitbol C, Montane B, Zilleruelo G. Angiotensin blockade as a sole treatment for proteinuric kidney disease in children. Nephrology, Dialysis, Transplantation 2007 May;22(5):1332-7.
Diallo 2002
Donner 2002
Driss 2009
  • Driss A, Asare KO, Hibbert JM, Gee B, Adamkiewics TV, Stiles JK. Sickle cell disease in the post genomic era: a monogenic disease with a polygenic phenotype. Genomic Insights 2009;2009(2):23-48.
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins PT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Etteldorf 1952
  • Etteldorf JN, Tuttle AW, Clayton GW. Renal function studies in pediatrics. 1. Renal hemodynamics in children with sickle cell anemia. American Medical Association. American Journal of Diseases of Children 1952;83(2):185-91.
Falk 1994
  • Falk RJ, Jennette JC. Sickle cell nephropathy. Advances in Nephrology from the Necker Hospital 1994;23:133-47.
Fernandes 2010
  • Fernandes AP, Januario JN, Canqussu CB, de Macedo DL, Viana MB. Mortality of children with sickle cell disease: a population study. Jornal de Pediatria 2010;86(4):279-84.
Forrest 2012
Guasch 1996
Guasch 1997
Guasch 1999
  • Guasch A, Zayas CF, Eckman JR, et al. Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. Journal of the American Society of Nephrology 1999;10(5):1014-9.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration. [: Available from www.cochrane-handbook.org]
James 2010
Kato 2007
  • Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews 2007;21(1):37-47.
Kolesnyk 2010
  • Kolesnyk I, Struijk DG, Dekker FW, Krediet RT. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease. Netherlands Journal of Medicine 2010;68(1):15-23.
Kotiah 2009
Lerma 2010
  • Lerma EV. Sickle Cell Nephropathy: Treatment & Medication. http://emedicine.medscape.com/article/247004-treatment (accessed 17 October 2010).
Lottenberg 2005
  • Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology American Society of Hematology Education Program 2005:58-65.
MedlinePlus 2009
  • MedlinePlus. End-stage kidney disease. www.nlm.nih.gov/medlineplus/ency/article/000500.htm (accessed 24 October 2010).
National Screening Committee for SC and Thal 2006
  • National Screening Committee. NHS Sickle Cell and Thalassemia Screening Programme. London: NHS Sickle Cell and Thalassaemia Screening Programme, 2006.
NIH-NHLBI 2002
  • National Institute of Health, National Heart, Lung and Blood Institute, Division of Blood Diseases and Resources. The Management of Sickle Cell Disease. 4th Edition. NIH Publication, June 2002.
O'Grady 1989
Pawloski 2005
Pham 2000
Platt 1994
  • Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639-44.
Powars 1991
  • Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Annals of Internal Medicine 1991;115(8):614-20.
Quinn 2010
Reid 2006
  • Reid JL, Rubin PC, Walters MR. Lecture Notes; Clinical Pharmacology and Therapeutics. 7th Edition. Massachusetts: Blackwell Publishing, 2006.
Rxmed 1999
  • Rxmed. ACE inhibitors General Monograph. www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20A)/ACE%20INHIBITORS.html (accessed 17 October 2010).
Saborio 1999
Scheinman 2009
Schnog 2004
  • Schnog JB, Duits AJ, Muskiet FAJ, Cate HE, Rojer RA, Brandjes DPM. Sickle cell disease; a general overview. Netherlands Journal of Medicine 2004;62(10):364-74.
Serjeant 1992
  • Serjeant GR. Sickle Cell Disease. 2nd Edition. New York: Oxford Medical Publications, 1992.
Shamsham 2000
  • American Academy of Family Physicians. Essentials of the Diagnosis of Heart Failure. www.aafp.org/afp/20000301/1319.html (accessed on 14 March 2011).
Sharpe 2011
Steinberg 1999
Steinberg 2006
Steiner 2006
  • Steiner C, Miller J. HCUP Statistical Brief #21. Sickle Cell Disease Patients in U.S. Hospitals, 2004. www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf (accessed 15 April 2011).
Waller 2005
  • Waller DG, Renwick AG, Hillier K. Medical Pharmacology and Therapeutics. 2nd Edition. London: Elsevier Saunders, 2005.
Ware 2010
  • Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics 2010;156(1):66-70.
WebMD 2009
  • Comprehensive Metabolic Panel. www.webmd.com/a-to-z-guides/comprehensive-metabolic-panel-topic-overview July 9 2009 (accessed on 14 March 2011).
Wesson 2002
Wigfall 2000
  • Wigfall DR, Ware RE, Burchinal MR, Kinney TR, Foreman JW. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. Journal of Pediatrics 2000;136(6):749-53.
Xie 2008
  • Xie D, Joffe MM, Brunelli SM, Beck J, Chertow GM, Fink JC, et al. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clinical Journal of the American Society of Nephrology 2008;3(5):1332-8.
Zatz 1986
  • Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. Journal of Clinical Investigation 1986;77(6):1925-30.